Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen

Blood

Volumn 96, Issue 12, 2000, Pages 3663-3670

  Huang, T H ^a   Wu, P Y ^a   Lee, C N ^a   Huang, H I ^a   Hsieh, S L ^a   Kung, J ^a   Tao, M H ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HYBRID PROTEIN; IMMUNOGLOBULIN IDIOTYPE; MUTANT PROTEIN; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGEN PRESENTING CELL; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; IMMUNOBLOTTING; IMMUNOGENICITY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

EID: 0034554842     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.12.3663.h8003663_3663_3670     Document Type: Article

References (43)

1. Myeloma proteins as tumor-specific transplantation antigens
2. Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice
3. Tumor immunity induced by preimmunization with BALB/c mouse myeloma protein
4. Idiotype vaccination against murine B cell lymphoma: Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits
5. Idiotype vaccination against murine B cell lymphoma: Inhibition of tumor immunity by free idio-type protein
6. Idiotypic vaccination as a treatment for a B cell lymphoma
7. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1
8. Immunotherapy of established murine B cell lymphoma: Combination of idiotype immunization and cyclophosphamide
9. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors
10. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma
11. Idiotype-cytokine fusion proteins as cancer vaccines: Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor
12. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity
13. Enhanced antigen immunogenicity induced by bispecific antibodies
14. Adjuvant-independent immunization by immunotargeting antigens to MHC and non-MHC determinants in vivo
15. Enhancement of antigenic potency in vitro and immunogenicity in vivo by coupling the antigen to anti-immunoglobulin
16. Enhanced response to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction
17. The role of the CD28 receptor during T cell responses to antigen
18. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin
19. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules
20. Effect of gamma rays at the dihydrofolate reductase locus: Deletions and inversions
21. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2
22. Treatment of B-cell lymphoma with chimeric IgG and single-chain Fv antibody-interleukin-2 fusion proteins
23. Anti-TAPA-1 antibodies induce protein tyrosine phosphorylation that is prevented by increasing intracellular thiol levels
24. Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: Characterization and use as probes for the biology of the tumor in vivo and in vitro
25. Differential effects of CTLA-4 substitutions on the binding of human CD80 (B7-1) and CD88 (B7-2)
26. Enhanced antigen presentation using human Fc gamma receptor (monocyte/macrophage)-specific immunogens
27. Dendritic cells
28. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors
29. Binding stoichiometry of the cytotoxic T lymphocyte-associated molecule-4 (CTLA-4): A disulfide-linked homodimer binds two CD86 molecules
30. DNA immunization induces protective immunity against B-cell lymphoma
31. A fusion DNA vaccine that targets antigen-presenting cells increases protection from viral challenge
32. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule
33. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion
34. Treatment of murine lupus with CTLA4Ig
35. CD28/B7 system of T cell costimulation
36. Targeting improves the efficacy of a DNA vaccine against Corynebacterium pseudotuberculosis in sheep
37. A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines
38. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma
39. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function
40. Comparison of the effects of IL-3, granulocyte-macrophage colony-stimulating factor, and macrophage colony-stimulating factor in supporting monocyte differentiation in culture: Analysis of macrophage antibody-dependent cellular cytotoxicity
41. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells
42. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response
43. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma